In a report released today, Andrew D’silva from B.Riley FBR maintained a Buy rating on Eton Pharmaceuticals (ETON – Research
Category: Healthcare
H.C. Wainwright Thinks Sorrento Therapeutics’ Stock is Going to Recover
H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Sorrento Therapeutics (SRNE – Research Report) today and set a
What Made H.C. Wainwright Downgrade PDS Biotechnology’s Stock?
In a report released today, Joseph Pantginis from H.C. Wainwright downgraded PDS Biotechnology (PDSB – Research Report) to Hold. The
H.C. Wainwright Keeps Their Buy Rating on CytoDyn (CYDY)
In a report released today, Yi Chen from H.C. Wainwright reiterated a Buy rating on CytoDyn (CYDY – Research Report),
H.C. Wainwright Thinks Can-Fite BioPharma’s Stock is Going to Recover
In a report released today, Vernon Bernardino from H.C. Wainwright reiterated a Buy rating on Can-Fite BioPharma (CANF – Research
H.C. Wainwright Thinks Synlogic’s Stock is Going to Recover
H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Synlogic (SYBX – Research Report) today and set a price
Analysts Offer Insights on Healthcare Companies: Aurinia Pharmaceuticals (NASDAQ: AUPH), BerGenBio AS (Other OTC: BRRGF) and Eton Pharmaceuticals (NASDAQ: ETON)
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Aurinia Pharmaceuticals